Evaluation of the Efficacy of Novel Drugs and Combinations Against Extensively- and Pan-Drug Resistant Acinetobacter baumannii Isolates
Abstract
Acinetobacter baumannii, a Gram-negative, nosocomial, opportunistic pathogen is commonly infectious in immunocompromised patients. More specifically patients develop healthcare-associated infections (HAI) spanning beyond sepsis, pneumonia, meningitis, and urinary tract infections. Due to its rapid ability to acquire antibiotic resistance, it has raised the necessity to discern a novel therapeutic treatment that can be effectively used against the multidrug resistant (MDR) A. baumannii. Cooper University Hospital (CUH) faced an increased case load of patients that were infected with MDR A. baumannii. The patient isolates obtained from CUH were highly resistant to the 22 standard-of-care antibiotics. With the recent introduction of novel antibiotics released onto the market, the possibility of antimicrobial synergism between old and new drugs was tested. We tested to see if drug synergy existed between levofloxacin and cefepime, and levofloxacin and amikacin. We also studied the potency and potential synergism of the newer drug cefiderocol in combination with the 22 standard-of-care antibiotics. Levofloxacin and amikacin showed limited efficacy as a drug combination making it an ineffective option in a clinical setting. However, levofloxacin and cefepime showed promise as an effective therapeutic combination. Experimental studies with cefiderocol showed contamination, requiring future evaluation with cefiderocol. We plan to further explore the drug combination levofloxacin and…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.